Form SCHEDULE 13D/A - General Statement of Acquisition of Beneficial Ownership: [Amend]
SEC Accession No. 0000947871-25-000626
Filing Date
2025-06-23
Accepted
2025-06-23 17:08:50
Documents
2

Document Format Files

Seq Description Document Type Size
1 primary_doc.html SCHEDULE 13D/A  
1 primary_doc.xml SCHEDULE 13D/A 18343
2 JOINT FILING AGREEMENT ss4987777_ex9901.htm EX-99.1 6940
  Complete submission text file 0000947871-25-000626.txt   27096
Mailing Address 601 LEXINGTON AVENUE, 54TH FLOOR NEW YORK NY 1022-4629
Business Address 89 MEDINAT HAYEHUDIM STREET, 11TH FLOOR HERZLIYA L3 46766 212-739-6400
OrbiMed Israel BioFund GP Limited Partnership (Filed by) CIK: 0001569821 (see all company filings)

EIN.: 980697985 | State of Incorp.: L3 | Fiscal Year End: 1231
Type: SCHEDULE 13D/A

Mailing Address 22 EINSTEIN ST. FLOOR 4 NESS ZIONA L3 7414003
Business Address 22 EINSTEIN ST. FLOOR 4 NESS ZIONA L3 7414003 972 723942377
BiomX Inc. (Subject) CIK: 0001739174 (see all company filings)

EIN.: 823364020 | Fiscal Year End: 1231
Type: SCHEDULE 13D/A | Act: 34 | File No.: 005-90744 | Film No.: 251065809
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)